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Abstract
Background—In the Western world, bladder cancer is the fourth most common cancer in men 
and the eighth most common in women. Recurrences frequently occur and continued surveillance 
is necessary to identify and treat recurrent tumors. Efforts to identify risk factors that are 
potentially modifiable to reduce the rate of recurrence are needed.
Methods—We investigated cigarette smoking behavior and body mass index (BMI) at diagnosis 
for associations with bladder cancer recurrence in a population-based study of 726 bladder cancer 
patients in New Hampshire, US. Patients diagnosed with non-muscle invasive urothelial-cell 
carcinoma were followed to ascertain long-term prognosis. Analysis of time to recurrence was 
performed using multivariate Cox regression models.
Results—Smokers experienced shorter time to recurrence (continuing smoker HR 1.51 95%CI 
1.08-2.13). Although being overweight (BMI>24.9 kg/m2) at diagnosis was not a strong 
independent factor (HR 1.33 95%CI 0.94-1.89), among continuing smokers, being overweight 
more than doubled the risk of recurrence compared to smokers of normal weight (HR 2.67 95%CI 
1.14-6.28).
Conclusions—These observational results suggest that adiposity is a risk factor for bladder 
cancer recurrence, particularly among tobacco users. Future intervention studies are warranted to 
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evaluate whether both smoking cessation and weight reduction strategies reduce bladder tumor 
recurrences.
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Introduction
Bladder cancer is among the top ten most prevalent cancers worldwide [1]. In the Western 
world, bladder cancer is the fourth most common cancer in men, and eighth most common 
in women [2]. An estimated 54,610 new cases of bladder cancer and 10,820 deaths are 
expected for U.S. males in 2013 [3]. Bladder cancer risk is up to four-fold higher among 
smokers compared with non-smokers [4]. The median age at diagnosis is 65 [5], and greater 
than 90% of cases are urothelial cell carcinoma (UCC). Of these, 75% are non-muscle 
invasive [6]. Current treatments are often effective at eliminating primary disease but rates 
of recurrent disease are high, exceeding 40% [7]. Bladder cancer is among the most 
expensive malignancies to treat due to the need for frequent, painful procedures to identify 
and surgically resect recurrent tumors [8]. Non-muscle invasive tumors are prevalent in the 
population, with an estimated 500,000 patients with a history of urothelial cell carcinoma 
currently residing in the U.S. [2]. Predictors of recurrent bladder cancer include a history of 
recurrences, primary tumor characteristics, including multiplicity, tumor size, T category 
(depth of invasion), presence of carcinoma in situ, tumor grade, and patient gender [9]. To 
date, analyses of smoking and recurrence are suggestive, but have yielded somewhat 
inconsistent results [10-13]. Several studies report an increased risk of incident bladder 
cancer associated with obesity [14, 15], however, little data are available with regard to body 
mass index (BMI) and bladder cancer recurrence. Numerous studies focus on rare subtypes 
of bladder cancer and, to our knowledge, no studies on recurrence of non-muscle invasive 
tumors and BMI have been published. A recent study found no significant difference in 
recurrence or survival associated with BMI in a Japanese population diagnosed with upper 
tract urothelial carcinoma which is a rare, aggressive malignancy representing just 5% of 
urothelial neoplasms [16, 17]. A study of muscle invasive urothelial carcinoma patients 
treated by radical cystectomy found a decreased risk of osseous recurrence, however this 
study examined only tumor recurrences at secondary sites following radical cystectomy [18] 
and is not generalizable to the majority of bladder cancer patients that present with non-
invasive UCC.
Our study provides the unique opportunity to examine recurrence of non-muscle invasive 
tumors in the context of a large U.S. population-based patient cohort identified from the 
New Hampshire State Cancer Registry. We have collected detailed data on patient 
characteristics, behaviors, exposures and clinical information and performed long-term 
patient follow-up (up to 15 years) to test the hypothesis that smoking and BMI (as a measure 
of adiposity) are associated with tumor recurrence.
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Materials and Methods
Study population
We identified all incident bladder cancers among New Hampshire residents, ages 25 to 74 
years, diagnosed from July 1, 1994 to December 31, 2001 from the New Hampshire State 
Cancer Registry. Detailed methods have been described previously [19, 20]. Briefly, we 
interviewed a total of 857 individuals with bladder cancer, which was 85% of the cases 
confirmed to be eligible for the study. After re-review, 21 were non-cancer and 7 
undetermined, leaving n=829 tumors which were either deemed cancerous by 
histopathology re-review (~90%), or the original diagnosis if the pathology materials were 
unavailable. The histologic composition of these tumors was 817 urothelial-cell 
(transitional-cell) carcinoma (660 papillary urothelial cell carcinoma, 133 urothelial cell 
carcinoma, 4 papillary carcinoma, 20 carcinoma NOS), as well as 2 spindle cell carcinoma, 
3 small cell carcinoma, 5 squamous cell carcinoma, 2 adenocarcinoma. Omitting n=9 
participants with primary diagnosis dates >2 years prior to the diagnosis date assumed in the 
interview, a total of n=808 participants were diagnosed with urothelial-cell (transitional-cell) 
carcinoma of the bladder. We restricted our analyses to the participants with non-muscle 
invasive disease (n=726) as muscle invasive cases likely have a different clinical experience 
and prognosis [1].
Personal interviews
Informed consent was obtained from each participant. All procedures and study materials 
were approved by the Committee for the Protection of Human Subjects at Dartmouth 
College. Consenting participants underwent a detailed in-person interview, usually at their 
home. The main objectives of the study were not disclosed to the interviewers. To ensure 
consistent quality of the study interviewer, interviews were tape recorded with the consent 
of the participants and routinely monitored by the interviewer supervisor. Questionnaires 
covered detailed socio-demographic as well as medical, personal, and family history 
information.
Follow-up
Information on bladder cancer recurrences was obtained from medical records provided by 
the treating hospital(s) (both in and outpatient records, including any pathology reports) 
covering the follow-up period. Records were reviewed by an experienced, certified tumor 
registrar to abstract the data on bladder tumors occurring subsequent to the incident tumor. 
Hospital registry data were used if the medical record could not be obtained. The first 
recurrent tumor was defined as any tumor identified after a disease-free remission period, 
more than 90 days after the date of initial primary bladder tumor diagnosis. Persistent 
primary tumors that did not have a remission period were excluded from the analysis of 
recurrence (n=1). Time to first event was calculated as the time between the date of initial 
diagnosis and the first recurrence. The diagnosis of a tumor with a greater stage or grade 
than the initial primary bladder tumor was defined as progression. If no events were 
reported, the date the patient was last seen documented in the medical record was used for 
censoring. Life status (alive or deceased) was determined as of January 2011 using the 
Social Security and the National Death Indices (NDI). Survival time was calculated from the 
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date of initial diagnosis to date of death. Patients were re-contacted in 2007 and we obtained 
data from a brief questionnaire to collect information on continuing smoking after diagnosis.
Statistical analysis
For the analysis of prognosis, smoking status was available on n=716 non-muscle invasive 
urothelial cell carcinoma patients coded as: never smokers, former smokers (quit at or before 
diagnosis date), and continuing smokers (smokers who continued to smoke after diagnosis). 
Individuals without smoking data available after diagnosis were assumed to have maintained 
the smoking status collected at the diagnostic interview, as our data demonstrated that nearly 
all cases (93%) who reported smoking at diagnosis continued to smoke. Body mass index 
(BMI) was calculated from weight and height at diagnosis, as reported in this questionnaire 
on n=350 non-muscle invasive urothelial cell carcinoma patients according to common 
standards (kg/m2) and was used as a measure of adiposity. Using NIH guidelines, normal 
BMI was defined as ≤24.9 kg/m2; overweight (high BMI) was defined as BMI 25 kg/m2 - 
29.9 kg/m2; obesity was defined as ≥30 kg/m2.
The main goals of the statistical analysis were to assess the relationship between cigarette 
smoking status, being overweight, and bladder cancer recurrence among non-muscle 
invasive urothelial-cell carcinoma cases (n=726). Time to first recurrence analysis was 
performed using Kaplan-Meier plots and differences were assessed using the log-rank test. 
To adjust for additional factors related to patient survival, Cox-proportional hazards 
regression analysis was performed in non-muscle invasive tumors (stages 0 and I) with 
adjustment for age at diagnosis, gender, smoking status (never, former, continuing), as well 
as grade (low, high), presence of carcinoma in situ (TIS), first course treatment 
(transurethral resection (TURB), immunotherapy, chemotherapy, radiotherapy, cystectomy), 
tumor size (<3cm, ≥3cm), and multiplicity (single, >1) in the model. P values represent two-
sided statistical tests with statistical significance at P<0.05. Statistical significances of the 
interactions were assessed using likelihood ratio tests comparing the models with and 
without interaction terms.
Results
Medical data were reviewed on 94% of the cases (679 out of 726) and 75% of the cases (545 
out of 726) were followed >2 years. Follow-up times ranged from 3 months to 15 years, 
with a median of 6 years. Of the non-muscle invasive urothelial-cell carcinoma patients with 
follow-up data available, 55% experienced recurrences during a median of 5.6 years of post-
diagnosis follow-up time (Table 1). The median recurrence-free survival time was 4.2 years. 
Only 5% of the patients had tumors that progressed during the follow-up period and the 
median time to progression for these patients was 1 year. Recurrences were more common 
among older patients with primary tumor characteristics including high-grade or Tis, large 
size, or multiple primaries. Most (>95%) of the participants in this study are of Caucasian 
origin, reflecting the racial mix of the New Hampshire population; restricting to Caucasians 
does not appreciably alter our analyses (data not shown). At diagnosis, the majority of the 
bladder cancer cases had a BMI >=24.9 (74%), and 83% were current or former smokers. In 
addition to the medical record review, we also re-contacted the patients who were surviving 
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in 2007 (n=448). The response rate for the patient follow-up questionnaire to collect updated 
smoking status information was 85% (n=382). Of the smokers, 64% quit smoking at or 
before diagnosis, while 36% continued smoking after diagnosis.
Cigarette smoking was associated with shorter time to first recurrence (log-rank P=0.0096, 
Figure 1). After adjustment for age, gender, stage / grade, tumor size, multiplicity and 
treatment, patients were at a higher risk of recurrence if they had a history of smoking when 
compared to non-smokers, whether they continued smoking after diagnosis (HR 1.51 95%CI 
1.08-2.13) or quit at or before diagnosis (HR 1.61 95%CI 1.17-2.20; Table 2). We did not 
observe a difference in the rate of tumor progression associated with smoking, however the 
statistical power for this analysis was limited. Continued smoking after diagnosis, but not 
former smoking, was associated with shorter overall survival (continued smoking survival 
HR 3.42 95%CI 1.29-9.07; former smoking survival HR 1.69 95%CI 0.70-4.10).
We also evaluated the relationship between tumor recurrence and the time since smoking 
cessation among patients who reported that they had quit smoking. We observed a modest 
decrease in median years to recurrence associated with smoking more recently (Table 3). 
Patients who quit smoking within the past 18 years from diagnosis experienced a shorter 
time to recurrence (median 2.4 years), compared with a median of 4.7 years for those who 
quit greater than 29 years ago, and 9.8 years for never smokers (quitting within 1-18 years 
vs. never smokers HR 1.83 95%CI 1.30-2.59; Table 3).
Being overweight at diagnosis (BMI ≥ 24.9) was associated with a shorter time to bladder 
tumor recurrence (log-rank P=0.026, Figure 2). In a multivariate Cox regression analysis, 
high BMI at diagnosis remained modestly associated with an increased risk of recurrence 
(HR 1.33 95%CI 0.94-1.89) after adjustment for age, gender, smoking status, stage, grade, 
tumor size, multiplicity, and treatment (Table 4); however, among individuals who 
continued smoking in the follow-up period, those who were overweight were at greater risk 
for recurrence (HR 2.67 95%CI 1.14-6.28) (P for multiplicative interaction=0.239) (Table 
4). These overweight smokers experienced a median recurrence-free survival time of 1.9 
years, compared to 6.8 years for all other patients combined (log-rank P=0.0046, Figure 3). 
We did not observe a clear difference in time to progression (HR 1.56 95%CI 0.41-5.89), 
although the statistical power for this analysis was limited by few events. The effects of 
smoking and BMI did not differ by gender, or by immunotherapy treatment status (data not 
shown). Pack-years, as a dose measure of exposure to cigarette smoke, was not associated 
with increased risk of recurrence (P=0.98) and inclusion of pack-years in our model did not 
alter results appreciably (overweight current smoker HR 2.57 95%CI 1.08-6.12). We further 
considered whether the effects we observed for BMI might be due to diabetes, which is in 
itself associated with being overweight. We performed the analysis excluding the 20% of the 
patients who reported being diagnosed as diabetic; high BMI remained associated with a 
greater than two-fold hazard ratio in the continuing smokers (HR 2.43 95%CI 1.01-5.89).
Discussion
Bladder cancer is among the top ten most prevalent cancers worldwide [1]. Although the 
mean 10-year survival rate is nearly 70%, more than half of the patients experience recurrent 
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tumors which require extensive screening and treatment [8]. The association between 
adiposity and bladder cancer incidence has been inconsistent [15, 21]. The relationship 
between bladder cancer recurrence and BMI is also poorly understood and no studies of 
BMI on recurrence of non-muscle invasive urothelial tumors have been published to date to 
our knowledge. Our unique study with detailed long-term prognostic data on patients from 
the general population of New Hampshire, permitted us to evaluate BMI and smoking in 
relation to recurrent disease following the primary diagnosis of early stage bladder cancer. 
We identified BMI as a modifier of time to recurrence in patients who continued to smoke 
after diagnosis. Among continuing smokers, those who were overweight had a greater than 
two-fold increased risk of recurrence, compared to those of normal weight. Obesity and 
body mass are associated with recurrence of several cancers [22], including the recurrence 
of prostate cancer after radical prostatectomy [23].
The biological mechanism for obesity-related tumorigenesis is not yet well characterized, 
but many possibilities have been suggested. High levels of adipose tissue correlate with high 
levels of cholesterol, a precursor for the androgen testosterone, which stimulates epithelial 
cell proliferation [24, 25]. High adipose levels have also been correlated with high plasma 
levels of VEGF and FGF2 [26], which both stimulate proliferation of epithelial cells [24, 27, 
28]. Adipose tissue also secretes leptin, which has been implicated in enhancing 
angiogenesis [29] and, consequently, may also enhance tumor development. Adiposity has 
also been correlated with reduced mitochondrial function and in turn, increased circulating 
reactive oxygen species, which can cause DNA damage [22]. Obesity related psychological 
depression [30], increased circulating lipids [22], and cigarette smoke [31, 32] depress 
immune surveillance for tumor cells.
It is unclear whether the biologic mechanisms relating obesity to recurrences differ from 
those driving incident tumors. There are several mechanisms that seem to play a unique role 
in tumor recurrence. BMI has been studied extensively in the context of breast cancer 
prognosis, with high BMI significantly increasing risk of distant recurrences [33]. In breast, 
as well as in colon cancer patients, an insulin resistant phenotype characterized by over-
expression of insulin receptors in the tumor cells of obese patients is associated with poor 
prognosis [34]. Adipocytes have also been shown to create localized microenvironmental 
conditions that promote growth of circulating tumor cells deposited nearby [35]. 
Mechanistic studies to understand whether these obesity-related biologic factors are similar 
in the context of bladder cancer are necessary.
Our study is limited by its observational nature. While our study is representative of the 
New Hampshire population, the racial homogeneity of the state limits the generalizability of 
our findings. Nevertheless, the strengths of this population-based study lie in the recruitment 
of patients across diverse types of healthcare facilities throughout the state, the collection of 
detailed prognostic data, and the long duration of follow-up. Self-reported weight and height 
were used to compute body mass index. Previous studies show that inaccuracies in self-
reported BMI are skewed towards overweight individuals reporting a lower BMI than actual 
[36]. This underreporting would be expected to dampen the observed association with 
prognosis, rather than strengthen it. Additionally, we used a threshold to dichotomize BMI, 
thus misclassification only occurs if a reporting error spans the normal – overweight 
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threshold. Thus, the association between BMI and recurrence is unlikely to be due to BMI 
misclassification, and may be stronger than observed.
BMI and smoking are factors that are modifiable post-diagnosis. A large majority of patients 
in our study population were overweight or obese smokers. During our review, we did not 
observe widespread behavioral intervention efforts documented in the medical record, and 
few patients achieved weight loss or smoking cessation following the primary diagnosis. 
The effectiveness and clinical utility of various approaches to modifying these factors must 
be empirically determined in additional studies. Despite the high prevalence of recurrences, 
the reasonably high survival rates for non-muscle invasive bladder cancer patients may 
allow for a ‘teachable moment’ at the time of the primary diagnosis that should be utilized to 
improve the overall health and prognosis for patients [34]. Smoking cessation is an 
underutilized cost-effective intervention [37] that reduces risk of numerous diseases, 
including recurrent bladder cancer [10, 11]. Furthermore, with the advent of advanced 
bariatric weight loss interventions, as well as advances in health awareness programs, both 
active and passive weight loss interventions are increasingly obtainable. Physical activity 
after cancer diagnosis has been associated with longer cancer-specific and overall survival 
among early-stage breast, prostate and colorectal cancer patients, with current trials 
underway, including a 3-year structured physical activity intervention in colon cancer 
survivors. A low-fat diet intervention for early-stage breast cancer patients also resulted in 
weight loss and a lower rate of recurrence [34]. The results of this study contribute to the 
growing body of evidence implicating adiposity in addition to smoking as potentially 
modifiable predictors of bladder cancer recurrence [14]. Obesity and smoking are risk 
factors for multiple other types of cancer, as well as cardiovascular disease. Thus, 
interventions that promote weight reduction and smoking cessation in bladder cancer 
survivors have a significant sociological impact and improve overall health and longevity. 
Our findings highlight the importance of evaluating these individual and lifestyle factors as 
predictors of clinical outcomes in bladder cancer and present an opportunity for testing 
interventions in survivors to reduce risk of subsequent malignancies.
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Precis
BMI and smoking are associated with bladder cancer recurrence. Consideration of these 
lifestyle factors in diagnosis and intervention therapies should be examined in future 
studies.
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Figure 1. 
Bladder cancer recurrence by cigarette smoking status after diagnosis. The Kaplan-Meier 
plot indicates shorter time to recurrence among patients who reported being either former or 
continued smokers when compared to never smokers (Log-rank p=0.0096). Inset graphic 
shows relative group size of never (green; 17.2%), former (orange; 52.9%), and current (red; 
29.9%) smokers.
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Figure 2. 
Bladder cancer recurrence by BMI at diagnosis. The Kaplan-Meier plot indicates shorter 
time to recurrence for individuals who were overweight (BMI >24.9) at diagnosis compared 
with normal weight individuals (Log-rank p=0.026). Inset graphic shows relative group size 
of normal (blue; 26.6%) and overweight (red; 73.4%) individuals.
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Figure 3. 
Bladder cancer recurrence by BMI at diagnosis among continued cigarette smokers. The 
Kaplan-Meier plot indicates shorter time to recurrence for overweight (BMI >24.9) 
continuing smokers compared with all normal weight and non-smoking overweight patients 
(log-rank p=0.0046). Inset graphic shows relative group size of overweight smokers (red; 
18.9%) and all normal weight and non-smoking overweight patients combined (green; 
81.1%).
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Table 1
Characteristics of non-muscle invasive urothelial cell carcinoma cases.
Overall N (%) Non-recurrent N (%) Recurrent N (%) Univariate P-value
Gender Female 171 (24) 77 (25) 80 (21)
Male 555 (76) 229 (75) 293 (79) 0.18
total 726 306 373
Reference agea     <40 21 (3) 12 (4) 7(2)
    40-49 58 (8) 19 (6) 30 (8)
    50-59 172 (24) 81 (26) 82 (22)
    60-69 295 (41) 119 (39) 160 (43)
    >=70 180 (25) 75 (10) 94 (13) 0.038
Race Caucasian 693 (97) 292 (97) 355 (97)
Other 22 (3) 10 (3) 12 (3) 0.91
Tumor Type TaT1 Low-grade 538 (74) 254 (83) 246 (66)
TaT1 High-grade 142 (20) 37 (12) 98 (26) 0.0025
Tis 46 (6) 15 (5) 29 (8) <0.0001
Treatment TURB 539 (75) 229 (75) 273 (73)
TURB + other 112 (16) 41 (13) 69 (18) 0.0154
other 68 (9) 34 (11) 31 (8) 0.038
Tumor Size <3cm 435 (64) 201 (70) 136 (83)
>3cm 241 (33) 86 (30) 27 (17) 0.0028
Multiplicity Single 749 (72) 226 (80) 223 (66)
>1 185 (28) 58 (20) 116 (34) 0.0001
Follow-up time 25th 1.7 years 1.56 years 2.1 years
50th 5.6 years 4.54 years 6.6 years
75th 9.2 years 8.91 years 9.6 years
95th 12.4 years 12.6 years 12.2 years
Data were missing on race n=11, smoking n=10, treatment n=7, size n=50, multiplicity n=62, follow-up n=47.
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Table 2
Bladder cancer recurrence and smoking after diagnosis.
Time to recurrence
Smoking status at follow-up N (%) Median years HR* (95%CI) P-value
Never 123 (17) 9.76 1.00 (ref)
Former 379 (53) 3.48 1.61 (1.17 - 2.20) 0.0031
Continuing 214 (30) 5.14 1.51 (1.08 - 2.13) 0.018
*
adjusted for age, gender, stage/grade, treatment, smoking status, tumor size, and multiplicity.
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Table 3
Bladder cancer recurrence and time since smoking cessation.
Time to recurrence
Smoking status N (%) Median years HR* (95%CI)
Never smoker 123 (27) 9.76 1.00 (ref)
Quit ≥29 yrs prior 83 (18) 4.68 1.37 (0.89 - 2.10)
Quit 19-28 yrs prior 73 (16) 3.57 1.44 (0.94 - 2.21)
Quit 1-18 yrs prior 184 (40) 2.39 1.83 (1.30 - 2.59)
*
adjusted for age, gender, stage/grade, treatment, smoking status, tumor size, and multiplicity.
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